Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Major Shareholder Braden Michael Leonard Acquires 17,716 Shares

Aclaris Therapeutics, Inc. (NASDAQ:ACRS) major shareholder Braden Michael Leonard acquired 17,716 shares of the firm’s stock in a transaction dated Monday, July 22nd. The stock was bought at an average cost of $1.33 per share, with a total value of $23,562.28. Following the acquisition, the insider now owns 13,602,691 shares in the company, valued at $18,091,579.03. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Large shareholders that own at least 10% of a company’s shares are required to disclose their transactions with the SEC.

Braden Michael Leonard also recently made the following trade(s):

• On Thursday, July 18th, Braden Michael Leonard acquired 130,317 shares of Aclaris Therapeutics stock. The stock was bought at an average cost of $1.30 per share, with a total value of $169,412.10.
• On Friday, July 5th, Braden Michael Leonard acquired 123,017 shares of Aclaris Therapeutics stock. The stock was bought at an average cost of $1.15 per share, with a total value of $141,469.55.
• On Wednesday, July 3rd, Braden Michael Leonard purchased 143,288 shares of Aclaris Therapeutics stock. The stock was acquired at an average cost of $1.16 per share, with a total value of $166,214.08.
• On Monday, July 1st, Braden Michael Leonard purchased 107,434 shares of Aclaris Therapeutics stock. The stock was acquired at an average cost of $1.14 per share, with a total value of $122,474.76.
• On Thursday, June 27th, Braden Michael Leonard purchased 235,000 shares of Aclaris Therapeutics stock. The stock was acquired at an average cost of $1.15 per share, with a total value of $270,250.00.
• On Monday, June 17th, Braden Michael Leonard purchased 150,000 shares of Aclaris Therapeutics stock. The stock was acquired at an average cost of $1.13 per share, with a total value of $169,500.00.
• On Thursday, June 13th, Braden Michael Leonard purchased 528,621 shares of Aclaris Therapeutics stock. The stock was acquired at an average cost of $1.15 per share, with a total value of $607,914.15.
• On Tuesday, June 11th, Braden Michael Leonard purchased 1,000,000 shares of Aclaris Therapeutics stock. The stock was acquired at an average cost of $1.08 per share, with a total value of $1,080,000.00.

Aclaris Therapeutics Price Performance

Shares of Aclaris Therapeutics stock opened at $1.38 on Thursday. The business has a 50 day simple moving average of $1.18 and a two-hundred day simple moving average of $1.20. Aclaris Therapeutics, Inc. has a 12 month low of $0.59 and a 12 month high of $10.15. The stock has a market capitalization of $98.34 million, a P/E ratio of -1.27 and a beta of 0.27.

Aclaris Therapeutics (NASDAQ:ACRS) last posted its quarterly earnings results on Tuesday, May 7th. The biotechnology company reported ($0.24) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.28) by $0.04. The business had revenue of $2.40 million during the quarter, compared to analyst estimates of $1.99 million. Aclaris Therapeutics had a negative return on equity of 61.03% and a negative net margin of 248.28%. As a group, research analysts anticipate that Aclaris Therapeutics, Inc. will post -0.78 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities analysts recently weighed in on the company. StockNews.com cut Aclaris Therapeutics from a “hold” rating to a “sell” rating in a report on Tuesday, April 2nd. HC Wainwright reissued a “neutral” rating on shares of Aclaris Therapeutics in a report on Monday. One investment analyst has rated the stock with a sell rating, six have given a hold rating and one has assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and an average target price of $22.25.

Institutional Investors Weigh In On Aclaris Therapeutics

Large investors have recently made changes to their positions in the stock. BML Capital Management LLC purchased a new stake in shares of Aclaris Therapeutics in the fourth quarter valued at approximately $686,000. Vanguard Group Inc. grew its position in shares of Aclaris Therapeutics by 1.0% in the third quarter. Vanguard Group Inc. now owns 3,363,046 shares of the biotechnology company’s stock valued at $23,037,000 after purchasing an additional 33,482 shares in the last quarter. Monaco Asset Management SAM purchased a new stake in shares of Aclaris Therapeutics in the fourth quarter valued at approximately $1,028,000. Octagon Capital Advisors LP purchased a new stake in shares of Aclaris Therapeutics in the fourth quarter valued at approximately $105,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank grew its position in shares of Aclaris Therapeutics by 115.5% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 43,784 shares of the biotechnology company’s stock valued at $46,000 after purchasing an additional 23,467 shares in the last quarter. 98.34% of the stock is currently owned by hedge funds and other institutional investors.

Aclaris Therapeutics Company Profile

Aclaris Therapeutics, Inc a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases.